A Phase IIIb study of MabThera® (rituximab) maintenance therapy in patients with follicular Non-Hodgkin’s Lymphoma who have responded to induction therapy. Maintenance Rituximab in Follicular Lymphoma...

Update Il y a 4 ans
Reference: EUCTR2005-004977-12

A Phase IIIb study of MabThera® (rituximab) maintenance therapy in patients with follicular Non-Hodgkin’s Lymphoma who have responded to induction therapy. Maintenance Rituximab in Follicular Lymphoma (MAXIMA)

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To evaluate the safety of rituximab maintenance therapy following a rituximab-containing induction regimen in first line or relapsed patients with follicular Non-Hodgkin’s Lymphoma


Inclusion criteria

  • First line or relapsed patients with Grade 1, 2 or 3a, CD20+ follicular non- Hodgkins's Lymphoma who respond to rituximab- containing induction therapy